Role of sildenafil in neurological disorders

Clinical Neuropharmacology

Volumn 31, Issue 6, 2008, Pages 353-362

  Farooq, Muhammad U ^a   Naravetla, Bharath ^a   Moore, Philip W ^b   Majid, Arshad ^a   Gupta, Rishi ^a   Kassab, Mounzer Y ^a,c  

^a East Lansing   (United States)

^b BroMenn Healthcare ^*  (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Amnesia; Cerebrovascular disorders; Intracranial hemorrhage; Neurodegenerative; Optic neuropathy; Phosphodiesterase 5 inhibitor; Retinal and ocular disorders; Seizures; Sildenafil; Subarachnoid hemorrhage

Indexed keywords

CYCLIC GMP; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; CYCLIC GMP PHOSPHODIESTERASE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONE;

ANGIOGENESIS; ARTICLE; ATROPHY; BRAIN HEMORRHAGE; BRANCH RETINAL ARTERY OCCLUSION; CEREBROVASCULAR ACCIDENT; ERECTILE DYSFUNCTION; HEADACHE; HEMODYNAMICS; HUMAN; ISCHEMIC OPTIC NEUROPATHY; MEDICAL RESEARCH; MIGRAINE; MULTIPLE SCLEROSIS; NERVOUS SYSTEM DEVELOPMENT; NEUROLOGIC DISEASE; NONHUMAN; OPHTHALMOPLEGIA; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RETINA MACULA DEGENERATION; SEIZURE; SPINAL CORD INJURY; SUBARACHNOID HEMORRHAGE; TRANSIENT GLOBAL AMNESIA; ANIMAL; CENTRAL NERVOUS SYSTEM; DOG; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; MALE; METABOLISM; MOUSE; PATHOPHYSIOLOGY; RAT; REVIEW; SMOOTH MUSCLE FIBER;

3',5'-CYCLIC-GMP PHOSPHODIESTERASES; ANIMALS; CENTRAL NERVOUS SYSTEM; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERECTILE DYSFUNCTION; HUMANS; MALE; MICE; MYOCYTES, SMOOTH MUSCLE; NERVOUS SYSTEM DISEASES; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PIPERAZINES; PURINES; RATS; SULFONES;

EID: 59849087724     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e31815cd94c     Document Type: Article

References (74)

1. Kruuse C, Thomsen LL, Jacobsen TB, et al. The phosphodiesterase 5 inhibitor sildenafil has no effect on cerebral blood flow or blood velocity, but nevertheless induces headache in healthy subjects. J Cereb Blood Flow Metab 2002;22: 1124-1131.
2. FDA sildenafil citrate information. Available at: http://www.fda.gov/ cder/consumerinfo/viagra/.
3. Desouza C, Parulkar A, Lumpkin D, et al. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 2002;25:1336-1339.
4. Diomedi M, Sallustio F, Rizzato B, et al. Sildenafil increases cerebrovascular reactivity: a transcranial Doppler study. Neurology 2005;65:919-921.
5. Kruuse C, Frandsen E, Schifter S, et al. Plasma levels of cAMP, cGMP and CGRP in sildenafil-induced headache. Cephalalgia 2004;24:547-553.
6. Morales AGC, Collins M, Wicker PA, et al. Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction. Int J Impot Res 1998;10:69-73.
7. Zusman RM, Morales A, Glasser DB, et al. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 1999;83:35C-44C.
8. Pfizer Labs. Viagra US Physician Prescribing Information. Division of Pfizer, Inc, NY; 2006:1-24.
9. Arnavaz A, Aurich A, Weissenborn K, et al. Effect of sildenafil (Viagra) on cerebral blood flow velocity: a pilot study. Psychiatry Res 2003;122:207-209.
10. Erceg S, Monfort P, Hernandez-Viadel M, et al. Oral administration of sildenafil restores learning ability in rats with hyperammonemia and with portacaval shunts. Hepatology 2005;41: 299-306.
11. Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery 1980;6:1-9.
12. Johnston KC. Effect of sildenafil (Viagra) on cerebral blood vessels. Neurology 2005;65:785.
13. Dora B, Balkan S. Exaggerated interictal cerebrovascular reactivity but normal blood flow velocities in migraine without aura. Cephalalgia 2002;22:288-290.
14. Gilad R, Lampl Y, Eshel Y, et al. Tonic-clonic seizures in patients taking sildenafil. BMJ. 2002; 325:869.
15. Riazi K, Roshanpour M, Rafiei-Tabatabaei N, et al. The proconvulsant effect of sildenafil in mice: role of nitric oxide-cGMP pathway. Br J Pharmacol 2006;147:935-943.
16. Ballard SA, Gingell CJ, Tang K, et al. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 1998;159:2164-2171.
17. Shimizu-Albergine M, Rybalkin SD, Rybalkina IG, et al. Individual cerebellar Purkinje cells express different cGMP phosphodiesterases (PDEs): in vivo phosphorylation of cGMP-specific PDE (PDE5) as an indicator of cGMP-dependent protein kinase (PKG) activation. J Neurosci 2003;23: 6452-6459.
18. Thompson WJ, Appleman MM. Multiple cyclic nucleotide phosphodiesterase activities from rat brain. Biochemistry 1971;10:311-316.
19. Barnes AP, Livera G, Huang P, et al. Phosphodiesterase 4D forms a cAMP diffusion barrier at the apical membrane of the airway epithelium. J Biol Chem 2005;280:7997-8003.
20. Burns F, Rodger IW, Pyne NJ. The catalytic subunit of protein kinase A triggers activation of the type V cyclic GMP-specific phosphodiesterase from guinea-pig lung. Biochem J 1992;283(Pt 2): 487-491.
21. Omori K, Kotera J. Overview of PDEs and their regulation. Circ Res 2007;100:309-327.
22. Yan C, Miller CL, Abe J. Regulation of phospho-diesterase 3 and inducible cAMP early repressor in the heart. Circ Res 2007;100:489-501.
23. Atalay B, Caner H, Cekinmez M, et al. Systemic administration of phosphodiesterase V inhibitor, sildenafil citrate, for attenuation of cerebral vasospasm after experimental subarachnoid hemorrhage. Neurosurgery 2006;59:1102-1107; discussion 1107-1108.
24. Wheeler MA, Ayyagari RR, Wheeler GL, et al. Regulation of cyclic nucleotides in the urinary tract. J Smooth Muscle Res 2005;41:1-21.
25. Inoha S, Inamura T, Ikezaki K, et al. Type V phosphodiesterase expression in cerebral arteries with vasospasm after subarachnoid hemorrhage in a canine model. Neurol Res 2002;24:607-612.
26. Rosengarten B, Schermuly RT, Voswinckel R, et al. Sildenafil improves dynamic vascular function in the brain: studies in patients with pulmonary hypertension. Cerebrovasc Dis 2006; 21:194-200.
27. Morgan JC, Alhatou M, Oberlies J, et al. Transient ischemic attack and stroke associated with sildenafil (Viagra) use. Neurology 2001;57:1730-1731.
28. Habek M, Petravić D. Stroke-an adverse reaction to sildenafil. Clin Neuropharmacol. 2006;29:165-167.
29. Li H, Forstermann U. Nitric Oxide in the pathogenesis of vascular disease. J Pathol 2000; 190:244-254.
30. Zhang Z, Reif D, Macdonald J, et al. ARL 17477, a potent and selective neuronal NOS inhibitor decreases infarct volume after transient middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab 1996;16:599-604.
31. Zhang R, Zhang L, Zhang Z, et al. A nitric oxide donor induces neurogenesis and reduces functional deficits after stroke in rats. Ann Neurol 2001;50: 602-611.
32. Zhang R, Wang L, Zhang L, et al. Nitric oxide enhances angiogenesis via the synthesis of vascular endothelial growth factor and cGMP after stroke in the rat. Circ Res 2003;92:308-313.
33. Bussolati B, Dunk C, Grohman M, et al. Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. Am J Pathol 2001;159: 993-1008.
34. Kroll J, Waltenberger J. A novel function of VEGF receptor-2 (KDR): rapid release of nitric oxide in response to VEGF-A stimulation in endothelial cells. Biochem Biophys Res Commun 1999;265: 636-639.
35. Buxton N, Flannery T, Wild D, et al. Sildenafil (Viagra)-induced spontaneous intracerebral haemorrhage. Br J Neurosurg 2001;15:347-349.
36. Monastero R, Pipia C, Camarda LK, et al. Intracerebral haemorrhage associated with sildenafil citrate. J Neurol 2001;248:141-142.
37. Marti I, Marti Masso JF. Hemiballism due to sildenafil use. Neurology 2004;63:534.
38. Donahue SP, Taylor RJ. Pupil-sparing third nerve palsy associated with sildenafil citrate (Viagra). Am J Ophthalmol 1998;126:476-477.
39. Laties A, Sharlip I. Ocular safety in patients using sildenafil citrate therapy for erectile dysfunction. J Sex Med 2006;3:12-27.
40. Lawes CM, Bennett DA, Feigin VL, et al. Blood pressure and stroke: an overview of published reviews. Stroke 2004;35:776-785.
41. Ballard S, Gingell CJ, Tang K, et al. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 1998;159:2164-2171.
42. Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998;338: 1397-1404.
43. Brenner S. Sildenafil increases cerebrovascular reactivity: a transcranial Doppler study. Neurology 2006;66:1455-1456.
44. de L. Figuerola, M, Bruera O, Leston J, et al. Cluster headache attack due to sildenafil intake. Cephalalgia 2006;26:617-619.
45. Evans RW. Sildenafil can trigger cluster headaches. Headache 2006;46:173-174.
46. Inoha S, Inamura T, Ikezaki K, et al. Type V phosphodiesterase expression in cerebral arteries with vasospasm after subarachnoid hemorrhage in a canine model. Neurol Res 2002;24: 607-612.
47. Teunissen LL, Rinkel GJ, Algra A. Risk factors for subarachnoid hemorrhage: a systematic review. Stroke 1996;27:544-549.
48. Gorelick PB, Sacco RL, Smith DB, et al. Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAMA 1999;281: 1112-1120.
49. Solenski NJ, Haley EC, Jr Kassell NF, et al. Medical complications of aneurysmal subarachnoid hemorrhage: a report of the multicenter, cooperative aneurysm study. Participants of the Multicenter Cooperative Aneurysm Study. Crit Care Med 1995;23:1007-1017.
50. Manno EM. Subarachnoid hemmorhage. Neurol Clin 2004;22:347-366.
51. Wang X, Mori T, Sumii T, et al. Hemoglobin-induced cytotoxicity in rat cerebral cortical neurons: caspase activation and oxidative stress. Stroke 2002;33: 1882-1888.
52. Gandolfo C, Sugo A, Del Sette M. Sildenafil and transient global amnesia. Neurol Sci 2003;24: 145-146.
53. Savitz SA, Caplan LR. Transient global amnesia after sildenafil (Viagra) use. Neurology 2002;59:778.
54. Schiefer J, Sparing R. Transient global amnesia after intake of tadalafil, a PDE-5 inhibitor: a possible association? Int J Impot Res 2005;17:383-384.
55. Devan BD, Bowker JL, Duffy KB, et al. Phosphodiesterase inhibition by sildenafil citrate attenuates a maze learning impairment in rats induced by nitric oxide synthase inhibition. Psychopharmacology (Berl) 2006;183:439-445.
56. Devan BD, Sierra-Mercado D Jr, Jimenez M, et al. Phosphodiesterase inhibition by sildenafil citrate attenuates the learning impairment induced by blockade of cholinergic muscarinic receptors in rats. Pharmacol Biochem Behav 2004;79: 691-699.
57. Fowler CJMJ, Sharief MK, Hussain IF, et al. A double blind, randomised study of sildenafil citrate for erectile dysfunction in men with multiple sclerosis. J Neurol Neurosurg Psychiatry 2005;76:700-705.
58. Giammusso B, Raffaele R, Vecchio I, et al. Sildenafil in the treatment of erectile dysfunction in elderly depressed patients with idiopathic Parkinson's disease. Arch Gerontol Geriatr Suppl 2002;8: 157-163.
59. Hussain IF, Brady CM, Swinn MJ, et al. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 2001;71:371-374.
60. Hurwitz RL, Ann S, Bunt-Milamall H, et al. cGMP phosphodiesterase in rod and cone outer segments of the retina. J Biol Chem 1985;260:568-573.
61. Vobig MA, Klotz T, Staak M, et al. Retinal side-effects of sildenafil. Lancet 1999;353:375.
62. Tripathi A, O'Donnell NP. Branch retinal artery occlusion; another complication of sildenafil. Br J Ophthalmol 2000;84:934-935.
63. Sponsel WE, Paris G, Sandoval SS, et al. Sildenafil and ocular perfusion. N Engl J Med 2000;342:1680.
64. Vobig MA. Retinal side-effects of sildenafil. Lancet 1999;353:1442.
65. Birch D, Toler SM, Swanson WH, et al. A double-blind placebo-controlled evaluation of the acute effects of sildenafil citrate (Viagra) on visual function in subjects with early-stage age-related macular degeneration. Am J Ophthalmol 2002;133: 665-672.
66. Cunningham AV, Smith KH. Anterior ischemic optic neuropathy associated with viagra. J Neuroophthalmol 2001;21:22-25.
67. Egan R, Pomeranz H. Sildenafil (Viagra) associated anterior ischemic optic neuropathy. Arch Ophthalmol 2000;118:291-292.
68. Pomeranz HD, Smith KH, Hart WM Jr, et al. Sildenafil-associated nonarteritic anterior ischemic optic neuropathy. Ophthalmology 2002;109: 584-587.
69. Fraunfelder FW, Pomeranz HD, Egan RA. Nonarteritic anterior ischemic optic neuropathy and sildenafil. Arch Ophthalmol 2006;124:733-734.
70. Gandhi JS. Sildenafil-associated NAION. Ophthalmology. 2003;110:1860-1861; author reply 1861.
71. Gorkin L, Hvidsten K, Sobel RE, et al. Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy. Int J Clin Pract 2006; 60:500-503.
72. Fowler CJ, Miller JR, Sharief MK, et al. A double blind, randomised study of sildenafil citrate for erectile dysfunction in men with multiple sclerosis. J Neurol Neurosurg Psychiatry 2005;76:700-705.
73. Giuliano F, Hultling C, El Masry WS, et al. Randomized trial of sildenafil for the treatment of erectile dysfunction in spinal cord injury. Sildenafil Study Group. Ann Neurol 1999;46:15-21.
74. Zesiewicz TA, Helal M, Hauser RA. Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson's disease. Mov Disord 2000;15: 305-308.